Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease Progression

Huntington disease (HD) is a fatal neurodegenerative disorder, with no effective treatment. The pathogenic mechanisms underlying HD have not been elucidated, but weight loss, associated with chorea and cognitive decline, is a characteristic feature of the disease that is accessible to investigation. We, therefore, performed a multiparametric study exploring body weight and the mechanisms of its loss in 32 presymptomatic carriers and HD patients in the early stages of the disease, compared to 21 controls. We combined this study with a multivariate statistical analysis of plasma components quantified by proton nuclear magnetic resonance (1H NMR) spectroscopy. We report evidence of an early hypermetabolic state in HD. Weight loss was observed in the HD group even in presymptomatic carriers, although their caloric intake was higher than that of controls. Inflammatory processes and primary hormonal dysfunction were excluded. 1H NMR spectroscopy on plasma did, however, distinguish HD patients at different stages of the disease and presymptomatic carriers from controls. This distinction was attributable to low levels of the branched chain amino acids (BCAA), valine, leucine and isoleucine. BCAA levels were correlated with weight loss and, importantly, with disease progression and abnormal triplet repeat expansion size in the HD1 gene. Levels of IGF1, which is regulated by BCAA, were also significantly lower in the HD group. Therefore, early weight loss in HD is associated with a systemic metabolic defect, and BCAA levels may be used as a biomarker, indicative of disease onset and early progression. The decreased plasma levels of BCAA may correspond to a critical need for Krebs cycle energy substrates in the brain that increased metabolism in the periphery is trying to provide

A propos de l'évaluation des troubles métaboliques liés au syndrome des ovaires polykystiques

CHATENAY M.-PARIS 11-BU Pharma. (920192101) / SudocSudocFranceF

Increased Infiltration of Macrophages in Omental Adipose Tissue Is Associated With Marked Hepatic Lesions in Morbid Human Obesity

International audienceIn human obesity, white adipose tissue (WAT) is enriched in macrophages. How macrophage infiltration in WAT contributes to the complications of obesity is unknown. This study tested the hypothesis that recruitment of macrophages in omental WAT is associated with hepatic damage in obese patients. Paired biopsies of subcutaneous and omental WAT and a liver biopsy were collected during gastric surgery in 46 obese women and 9 obese men (BMI 47.9 0.93 kg/m 2). The number of HAM56 macrophages in WAT was quantified microscopically, and correlations with clinical and biological parameters and histological liver pathology were investigated. There were twice as many macrophages in omental as in subcutaneous WAT (P < 0.0001). After adjustment for age, omental WAT macrophage infiltration was correlated to fasting glucose and insulin, quantitative insulin sensitivity check index, triglycerides, aspartate aminotransferase (AST), and-glutamyltranspeptidase. We propose an easy equation to estimate the amount of macrophages in omental WAT. Increased macrophage accumulation specifically in omental WAT was associated with hepatic fibroinflammatory lesions (P 0.01). The best predictive model for the severity of hepatic damage includes adiponectinemia, AST, and omental WAT macro-phages. These data suggest that the presence of macrophages in omental WAT participates in the cellular mechanisms favoring hepatic fibroinflammatory lesions in obese patients

Partial least square (PLS) analyses of NMR spectra of plasma samples from HD patients with no or little signs of the disease and controls.

<p>Three groups of presymptomatic, early and mildly affected HD patients were constituted on the basis of their UHDRS scores, as described in the <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0000647#s2" target="_blank">methods</a>. The first and second components in the X space (NMR spectrum) are denoted PC<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0000647#pone.0000647-Gatchel1" target="_blank">[1]</a> and PC<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0000647#pone.0000647-Robbins1" target="_blank">[2]</a> respectively. PLS score plots (PC<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0000647#pone.0000647-Gatchel1" target="_blank">[1]</a>/PC<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0000647#pone.0000647-Robbins1" target="_blank">[2]</a>) of pair-wise compared groups show the greater variation within the NMR spectrum according to a priori classification with UHDRS. There is a clear separation between presymptomatic and early HD patients (a), as well as between early and mildly affected HD patients (b). Despite some overlap, presymptomatic mutation carriers can also be distinguished from controls (c).</p

Nutritional characteristics of patients with Huntington disease according to sex, compared to controls.

<p>The values represent the mean±standard deviations. Ranges are in parentheses. The HD group was compared to controls (ANOVA).</p>A<p>Determined retrospectively for a 5-year period.</p>B<p>Determined by bioelectric impedance.</p>C<p>Determined from a 3-day and a 24-hour questionnaire performed at a one-month interval. Weight loss was significant in the HD group, in both men and women. Despite significantly higher calories intake, carriers of huntingin mutations did not have a higher BMI (body mass index). In men, BMI and lean body mass were lower in the HD group despite higher food intake. These nutritional analyses demonstrate the existence of a hypermetabolic state in the early stages of HD.</p

Clinical characteristics of Huntington disease cohort.

*<p>Chorea subscore 28 maximal, worst, dystonia subscore 20 maximal, worst</p><p>The values represent the mean±standard deviations. Ranges are in parentheses. Comparisons of means (ANOVA) were made among the 3 HD groups. UHDRS  =  Unified Huntington disease rating scale, 120 is the maximal score of severity, up to 4 is considered as normal. The HD group included 15 strictly presymptomatic carriers, 10 patients at an early stage of the disease and 7 mildly affected patients. Ages at examination did not differ significantly among groups; presymptomatic HD carriers were not younger than affected patients. Total functional score was close to maximal in all groups, even in mildly affected patients, in whom the mean TFC was greater than 10. However, the depression score was pathological, even in presymptomatic carriers, and worsened with disease progression.</p

The levels of branched chain amino acids are significantly different in HD patients and controls.

<p>The concentrations of valine, leucine and isoleucine in plasma were determined by ion exchange chromatography. Comparisons of means (ANOVA) were made between men or women with HD and their respective controls. In men, there was a significant decrease of valine, leucine and isoleucine in the HD group. In women, similar results are observed for leucine and isoleucine.</p

Differences in the relative concentrations of branched chain amino acids in plasma are responsible for the differences among the HD groups.

<p>PLS-contribution plots allow comparison of plasma metabolic profiles in early affected HD patients and presymptomatic carriers. NMR variables that have the greatest weight (w*₁; scaled in units of standard deviation), therefore contributing most to the separation between HD groups, are decreased concentrations (>2SD) of metabolites located between 0.85 and 1.0 ppm: valine, leucine and isoleucine. A similar contribution plot was obtained when plasma metabolic profiles from mildly affected HD patients were compared to early HD patients (data not shown).</p

Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients.

Context: Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction is a rare and life-threatening manifestation of the antiphospholipid syndrome (APLS). Data on the long-term outcome are scarce. Objective: The aims of the present study were to analyze the long-term outcome related to APLS per se and to characterize the course of adrenal involvement. Design: We conducted a retrospective study of patients with bilateral adrenal hemorrhage-adrenal infarction secondary to APLS seen in the Department of Internal Medicine of Pitié-Salpêtrière Hospital in Paris (France) between January 1990 and July 2010. Results: Three patients died during the acute phase related to APLS manifestations. Sixteen patients (7 males; 9 females) were followed up during a median period of 3.5 years (range 0.3-28.1 years). Three episodes of recurrent thrombosis were noted. One patient died from cerebral hemorrhage 3 months after the onset of adrenal insufficiency. Repeated Synacthen tests showed complete absence of response in 8 of the 10 patients assessed; cortisol and aldosterone increased appropriately in one patient and to some extent in another one. Dehydroepiandrosterone levels and 24-hour urinary epinephrine levels remained abnormally low in all evaluated patients. Adrenal imaging performed more than 1 year after the initial event revealed completely atrophic glands in 9 of 11 patients. Conclusions: This particular subset of APLS patients who survive the acute phase has a rather favorable long-term outcome. Although adrenal dysfunction is generally irreversible, adrenocortical function may, at least partially, recover in rare cases. In this view, measurement of early morning cortisol during follow-up is indicated to detect these patients.Journal ArticleSCOPUS: ar.jinfo:eu-repo/semantics/publishe